🇺🇸 FDA

Company profile · Sponsor

Monte

Monte Rosa Therapeutics

GLUE · NYSE biotech BOSTON, MA, USA
Pipeline
7
Drugs
0
Patents
8

Quick answer

Monte (GLUE) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker GLUE
Exchange NYSE
Company type biotech
Headquarters BOSTON, MA, USA
SEC CIK 0001826457

Pipeline (7)

Search pipeline →

  1. Cabergoline 1 MG

    Monte

    Lactation Suppressed

    phase 2 small molecule completed

    1 trial

  2. Oral MRT-2359

    Monte

    NSCLC

    phase 2 small molecule active

    1 trial

  3. SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse

    Monte

    Bile acid diarrhoea

    phase 2 small molecule active

    1 trial

  4. MRT-6160

    Monte

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. MRT-8102

    Monte

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  6. Temozolomide

    Monte

    Brain Neoplasms, Malignant, Primary

    approved small molecule completed

    1 trial

  7. Vyndaqel 61 mg soft capsules

    Monte

    Transthyretin cardiac amyloidosis

    approved small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12391663

    Isoindolinone compounds

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12378199

    Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12257247

    Targeted degradation of VAV1

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12011619

    Low intensity focused ultrasound for treating cancer and metastasis

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Monte?

Monte (GLUE) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Monte sponsor?

We track 7 ClinicalTrials.gov-linked programs for Monte, including Cabergoline 1 MG and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Monte company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.